Sheila Jonnatan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sheila Jonnatan has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Laura A. Sena
11The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Baltimore, Maryland
22 shared publications - Samuel R. Denmeade
Sidney Kimmel Comprehensive Cancer Center 1 Baltimore, Maryland
22 shared publications - David E. Sanin
Bloomberg-Kimmel Institute of Immunotherapy, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
21 shared publications - Elizabeth D. Thompson
W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland
21 shared publications - Varsha Vakkala
Sidney Kimmel Comprehensive Cancer Center 1 Baltimore, Maryland
21 shared publications - Angelo Michael De Marzo
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University, School of Medicine Baltimore MD USA
20 shared publications
Latest Publications
- 20 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- p. OF1-OF9
Immunometabolic Effects of Oral Testosterone for Castration-Resistant Prostate Cancer in the ACROBAT Trial
High-dose testosterone is an emerging treatment option for selected patients with castration-resistant prostate cancer (CRPC), but its efficacy is limited by frequent primary and acquired resistance. Preclinical studies suggest that high-dose testosterone induces tumor metabolic reprogramming that promotes resistance; however, clinical validation is lacking. In the prospective ACcelerated ROunds of BAT (ACROBAT) trial, we performed longitudinal plasma metabolomic profiling and high-dimensional immune cell phenotyping of 10 patients with CRPC treated with high-dose oral testosterone undecanoate. Testosterone exposure increased circulating metabolites within the arginine–ornithine–polyamine axis, including guanidinoacetic acid, creatine, homoarginine, and N1-acetylspermidine. Notably, nonresponders exhibited elevated levels of circulating polyamines, including putrescine. Although we observed no significant changes in circulating immune cell subset frequencies, integrative analyses revealed positive associations between polyamine-related metabolites and immunosuppressive myeloid populations, including monocytic myeloid-derived suppressor cells (M-MDSC). Collectively, these data provide clinical evidence that high-dose testosterone therapy increases polyamine synthesis from arginine, which is associated with therapy resistance and abundance of immunosuppressive myeloid cells. Implications: High-dose testosterone treatment of patients with CRPC enrolled on the ACROBAT trial increased circulating polyamines, which were associated with nonresponse to treatment and greater abundance of circulating immunosuppressive myeloid cells.
- 20 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- p. OF1-OF9
Immunometabolic Effects of Oral Testosterone for Castration-Resistant Prostate Cancer in the ACROBAT Trial
High-dose testosterone is an emerging treatment option for selected patients with castration-resistant prostate cancer (CRPC), but its efficacy is limited by frequent primary and acquired resistance. Preclinical studies suggest that high-dose testosterone induces tumor metabolic reprogramming that promotes resistance; however, clinical validation is lacking. In the prospective ACcelerated ROunds of BAT (ACROBAT) trial, we performed longitudinal plasma metabolomic profiling and high-dimensional immune cell phenotyping of 10 patients with CRPC treated with high-dose oral testosterone undecanoate. Testosterone exposure increased circulating metabolites within the arginine–ornithine–polyamine axis, including guanidinoacetic acid, creatine, homoarginine, and N1-acetylspermidine. Notably, nonresponders exhibited elevated levels of circulating polyamines, including putrescine. Although we observed no significant changes in circulating immune cell subset frequencies, integrative analyses revealed positive associations between polyamine-related metabolites and immunosuppressive myeloid populations, including monocytic myeloid-derived suppressor cells (M-MDSC). Collectively, these data provide clinical evidence that high-dose testosterone therapy increases polyamine synthesis from arginine, which is associated with therapy resistance and abundance of immunosuppressive myeloid cells. Implications: High-dose testosterone treatment of patients with CRPC enrolled on the ACROBAT trial increased circulating polyamines, which were associated with nonresponse to treatment and greater abundance of circulating immunosuppressive myeloid cells.
- Open Access
- 8 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1021-1027
Castration Resistance Accelerates Prostate Cancer Kinetics
Background: Prostate cancer can be an indolent disease with which patients can live for many years. Thus, an understanding of how therapy and its ensuing resistance affect prostate cancer kinetics may guide efforts to determine optimal timing of therapy initiation. Despite the fact that castration has been used as therapy for prostate cancer for more than 70 years, no prior study has systematically quantified the effect of castration resistance on the rate of progression. The prostate‐specific antigen doubling time (PSADT) estimates prostate cancer kinetics and predicts overall survival, but whether PSADT changes as a result of castration resistance is not known. Methods: Here, we studied the longitudinal change in the PSADT before castration and following the development of castration resistance in a cohort of 40 patients with prostate cancer. Results: The PSADT of castration‐resistant prostate cancer (CR‐PSADT) was markedly shorter than the matched PSADT of castration‐naïve prostate cancer (CN‐PSADT) (median 2.6 months vs. 5.8 months, p < 0.001). The CR‐PSADT positively correlated with the CN‐PSADT and with overall survival. Sensitivity analysis suggested that the PSADT did not change as a function of time during progression when treatment was unchanged. Using a separate cohort of 36 patients with metastatic CRPC, we confirmed a positive correlation of CR‐PSADT with overall survival and identified a negative correlation with the Ki‐67 proliferation index of metastatic tumor biopsies. Conclusions: Castration‐resistant prostate cancer is associated with markedly accelerated disease kinetics compared with castration‐naïve prostate cancer. This acceleration of disease progression has the potential to shorten the survival of some patients with indolent disease who are treated prematurely with ADT.
- 8 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1021-1027
Open AccessCastration Resistance Accelerates Prostate Cancer Kinetics
Background: Prostate cancer can be an indolent disease with which patients can live for many years. Thus, an understanding of how therapy and its ensuing resistance affect prostate cancer kinetics may guide efforts to determine optimal timing of therapy initiation. Despite the fact that castration has been used as therapy for prostate cancer for more than 70 years, no prior study has systematically quantified the effect of castration resistance on the rate of progression. The prostate‐specific antigen doubling time (PSADT) estimates prostate cancer kinetics and predicts overall survival, but whether PSADT changes as a result of castration resistance is not known. Methods: Here, we studied the longitudinal change in the PSADT before castration and following the development of castration resistance in a cohort of 40 patients with prostate cancer. Results: The PSADT of castration‐resistant prostate cancer (CR‐PSADT) was markedly shorter than the matched PSADT of castration‐naïve prostate cancer (CN‐PSADT) (median 2.6 months vs. 5.8 months, p < 0.001). The CR‐PSADT positively correlated with the CN‐PSADT and with overall survival. Sensitivity analysis suggested that the PSADT did not change as a function of time during progression when treatment was unchanged. Using a separate cohort of 36 patients with metastatic CRPC, we confirmed a positive correlation of CR‐PSADT with overall survival and identified a negative correlation with the Ki‐67 proliferation index of metastatic tumor biopsies. Conclusions: Castration‐resistant prostate cancer is associated with markedly accelerated disease kinetics compared with castration‐naïve prostate cancer. This acceleration of disease progression has the potential to shorten the survival of some patients with indolent disease who are treated prematurely with ADT.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
FigureS1 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
SPA increases intracellular and extracellular polyamines in prostate cancer cell lines
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS1 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
SPA increases intracellular and extracellular polyamines in prostate cancer cell lines
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
FigureS4 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
AR-V7 can positively regulate ODC
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS4 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
AR-V7 can positively regulate ODC
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
FigureS13 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
Correlation of metabolites and PSA
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS13 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
Correlation of metabolites and PSA
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
FigureS2 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
SPA increases activity of ODC and AMD1 in prostate cancer cell lines
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS2 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
SPA increases activity of ODC and AMD1 in prostate cancer cell lines
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
FigureS11 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
Inhibition of ODC increases downregulation of MYC by SPA by depleting S-adenosylmethionine
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS11 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
Inhibition of ODC increases downregulation of MYC by SPA by depleting S-adenosylmethionine
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
FigureS12 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
Plasma metabolite analyses of trial participants
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS12 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
Plasma metabolite analyses of trial participants
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
Table S3 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
Table S3 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
FigureS9 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
DFMO decreases putrecine induced by SPA and does not increase efficacy of AR inhibition
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigureS9 from Androgen Receptor Drives Polyamine Synthesis, Creating a Vulnerability for Prostate Cancer
DFMO decreases putrecine induced by SPA and does not increase efficacy of AR inhibition